Lisa Astor


Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancer

September 28, 2022

Adding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.

Niraparib/abiraterone regimen shows early efficacy signals in metastatic prostate cancer

May 14, 2022

A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.